Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
Current Opinion in Immunology Volume 25, Issue 3, June 2013, Pages 389–395 Dendritic cell-based nanovaccines for cancer immunotherapyLeonie E Paulis1,Subhra Mandal1,Martin Kreutz,Carl G FigdorDepartment of Tumor Immunology, Nijmegen Center for Molecular Life Sciences, Radboud University Nijmegen Medical Center, Nijmegen, Netherlandshttp://dx.doi.org/10.1016/j.coi.2013.03.001, How to Cite or Link Using DOI 
No comment yet.
Sign up to comment
|
Scoop.it!
The pathogenesis of systemic lupus erythematosus—an update Jinyoung Choi1, *,Sang Taek Kim1, *,Joe Craft1, 2, 1 Department of Internal Medicine (Rheumatology), Yale School of Medicine, New Haven, CT 06520, United States2 Department of Immunobiology, Yale School of Medicine, New Haven, CT 06520, United States http://dx.doi.org/10.1016/j.coi.2012.10.004,
Systemic lupus erythematosus (SLE, lupus) is characterized by a global loss of self-tolerance with activation of autoreactive T and B cells leading to production of pathogenic autoantibodies and tissue injury. Innate immune mechanisms are necessary for the aberrant adaptive immune responses in SLE. Recent advances in basic and clinical biology have shed new light on disease mechanisms in lupus, with this review discussing the recent studies that offer valuable insights into disease-specific therapeutic targets.
The pathogenesis of systemic lupus erythematosus—an update [Current Opinion in Immunology—an update] http://t.co/gKMERgRK...
Gilbert C FAURE's comment,
August 17, 2013 11:26 AM
november 2012, a synthetic review of uptodate hypothesis
|
Cancer immunotherapy critically relies on the efficient presentation of tumor antigens to T-cells to elicit a potent anti-tumor immune response aimed at life-long protection against cancer recurrence. Recent advances in the nanovaccine field have now resulted in formulations that trigger strong anti-tumor responses. Nanovaccines are assemblies that are able to present tumor antigens and appropriate immune-stimulatory signals either directly to T-cells or indirectly via antigen-presenting dendritic cells. This review focuses on important aspects of nanovaccine design for dendritic cells, including the synergistic and cytosolic delivery of immunogenic compounds, as well as their passive and active targeting to dendritic cells. In addition, nanoparticles for direct T-cell activation are discussed, addressing features necessary to effectively mimic dendritic cell/T-cell interactions.